Utility of circulating tumor DNA for predicting prognosis in the management of resectable pancreatic cancer
-
Published:2022
Issue:
Volume:8
Page:29
-
ISSN:2454-2857
-
Container-title:Journal of Cancer Metastasis and Treatment
-
language:
-
Short-container-title:J Cancer Metastasis Treat
Author:
Tyerman Zachary,Ambler Emily,Schlick Cary Jo R.,Nwajei Felix,Chawla Akhil
Abstract
Background: The measurement of circulating tumor DNA (ctDNA) has been studied in several malignancies, including metastatic pancreatic cancer, but less is known about its utility in monitoring treatment response and recurrence in resectable pancreatic cancer. Methods: We conducted a systematic review of the literature examining the association of ctDNA with overall survival (OS) and disease-free survival. Results: Five articles met our exclusion criteria. Baseline and/or postoperative ctDNA was found to be associated with decreased OS and recurrence-free survival. Discussion: ctDNA has the potential to be used as a prognostic biomarker and to guide therapy in resectable pancreatic cancer.
Publisher
OAE Publishing Inc.